Company intelligence / Profile preview
Cyrus Biotechnology
Seattle, Washington, United Statescyrusbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CYR212, an engineered next-generation reduced-immunogenicity and half-life extended IgG protease, has been selected as clinical development candidate for chronic IgG-driven autoimmune disease. Preclinical studies showed significant extension of half-life and pharmacodynamic IgG-reducing activity compared to wild type IdeS protease, with rapid, titratable, dose-dependent and sustained depletion of IgG, and no immunogenicity response upon first or second dose in rabbits[9].
- Therapeutic areas
- GastroenterologyImmunologyInfectious Diseases
- Modalities
- BiologicsProteinsEnzymes
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Cyrus Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cyrus Biotechnology.